We are a pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing a broad portfolio of projects under development of therapeutic and diagnostic technologies to tackle unmet medical needs. Our principal office in Asia provides easy access to prosperous medical research resources and some of the worldâs most talented specialists and clinicians. We have established strong relationships and collaborations with leading academic institutions to propel therapeutic innovations. To date, Aptorum has obtained 12 exclusively licensed technologies in the areas of neurology, infectious diseases, gastroenterology, oncology, surgical robotics and natural health. Source
No articles found.
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the li...
SCYNEXIS, Inc. is a biotechnology company commi...
As of June 30, 2019, Sabraâs investment portfolio included 432 real estate prope...
As of June 30, 2019, Sabraâs investment portf...
The discovery of immunosuppressive (anti-rejection) drugs has made possible life-s...
The discovery of immunosuppressive (anti-reject...
Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is ap...
Lexicon Pharmaceuticals is a fully integrated b...
Join the National Investor Network and get the latest information with your interests in mind.